Preclinical studies using QSOX1 inhibitors as anti-neoplastic compounds

Preclinical studies using QSOX1 inhibitors as anti-neoplastic compounds Preclinical studies using QSOX1 inhibitors as anti-neoplastic compounds Preclinical studies using QSOX1 inhibitors as anti-neoplastic compounds Collect, annotate and run up to 1,000 COVID19 plasma, serum and whole blood samples of on lateral flow and similar assays using materials and reagents and protocols provided by Axim for continued development of NeuCovix test. Preclinical studies using QSOX1 inhibitors as anti-neoplastic compounds Two melanoma cell lines will be investigated for: 1. QSOX1 expression 2. Sensitivity to small molecules that inhibit QSOX1 enzymatic activity in cell 3D cell invasion assays. 3. Up to 6 small molecules will be tested per month Preclinical studies using QSOX1 inhibitors as anti-neoplastic compounds Preclinical studies using QSOX1 inhibitors as anti-neoplastic compounds Preclinical studies using QSOX1 inhibitors as anti-neoplastic compounds Preclinical studies using QSOX1 inhibitors as anti-neoplastic compounds